MOLECULAR MECHANISMS OF HIV1 DNA INTEGRATION
HIV1 DNA 整合的分子机制
基本信息
- 批准号:6150207
- 负责人:
- 金额:$ 22.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-09-01 至 2004-01-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
An essential step during the life cycle of all retroviruses, including
human immunodeficiency virus (HIV), is integration of a double-stranded
DNA copy of the viral genome into a chromosome of the host cell. Two
factors are critical for the integration process: the viral protein,
integrase, and sequences at the ends of the linear viral DNA. Integrase
removes two nucleotides from the 3' ends of a linear viral DNA molecule,
and subsequently mediates a coupled cleavage-ligation reaction during
which a staggered cut is made in the target DNA, and the resulting 5'
ends of the target DNA are covalently joined to the recessed 3' ends of
the viral DNA. The timing of the joining of the viral 5' ends to target
DNA is presently not known, and the protein factors involved remain to
be characterized. During integration, many sites in the host chromosome
can be used as targets, although a wide variation in integration
efficiency is observed among the target sites. The mechanism that
determines target site specificity is not well understood. Since
integration is required for retroviral replication and there is no
recognized counterpart to integrase in normal cellular function,
integration is an appealing target for developing specific inhibitors
against retroviruses. The broad, long-term objective of this proposal is
to further the understanding of the mechanism of HIV integration. The
specific aims are (A) to examine target site selection during retroviral
DNA integration, and (B) to study the kinetics and mechanisms of joining
of the viral 5' end to target DNA, a poorly characterized final step of
integration. The experimental design and methods for achieving these
goals arc. (1) to construct chimeric proteins between HIV-1 and FIV
integrases for determining the protein domain involved in selecting DNA
sites for integration, and to use a PCR-based selection and amplification
protocol for determining the DNA sequence optimal for integrase
recognition, (2) to explore site-directed integration by studying in
vitro and in vivo the activities and integration patterns of fusion
proteins consisting of integraSe and a sequence-specific DNA binding
protein, and (3) to use a novel strategy to study the timing of viral 3'-
and 5'-end joining, and to develop an in vitro system for characterizing
the 5'-end joining step and the factors required. The study may reveal
potential novel targets for inhibitors and provide useful assays for drug
screening. Information obtained from studying integration site selection
may lead to a new approach for inserting exogenous genes at specific
sites.
在所有逆转录病毒的生命周期中的一个重要步骤,
人类免疫缺陷病毒(HIV),是一种整合的双链
将病毒基因组的DNA拷贝到宿主细胞的染色体中。两
整合过程的关键因素是:病毒蛋白,
整合酶和线性病毒DNA末端的序列。整合酶
从线性病毒DNA分子的3 ′端除去两个核苷酸,
并随后介导偶联的裂解-连接反应,
其中在靶DNA中进行交错切割,并且得到的5'
靶DNA的末端共价连接到靶DNA的凹进的3'末端,
病毒DNA病毒5'端连接至靶分子的时机
DNA目前还不清楚,涉及的蛋白质因子仍然是未知的。
被定性。在整合过程中,宿主染色体上的许多位点
可以用作目标,尽管集成的变化很大,
在靶位点中观察到效率。的机制
决定靶位点特异性的因素尚不清楚。以来
逆转录病毒复制需要整合,
在正常细胞功能中与整合酶对应,
整合是开发特异性抑制剂的吸引人的目标
对抗逆转录病毒这项建议的广泛和长期目标是
进一步了解艾滋病毒整合的机制。的
具体目标是(A)检查逆转录病毒过程中的靶位点选择
DNA整合,和(B)研究连接的动力学和机制
将病毒5'端的DNA连接到靶DNA,这是一个表征不佳的最终步骤,
一体化实验设计和实现这些的方法
目标弧。(1)构建HIV-1和FIV的嵌合蛋白
用于确定参与选择DNA的蛋白质结构域的整合酶
整合位点,并使用基于PCR的选择和扩增
确定整合酶最佳DNA序列的方案
认识,(2)通过研究,
体外和体内的融合活性和整合模式
由整合和序列特异性DNA结合组成的蛋白质
蛋白质,和(3)使用一种新的策略来研究病毒3 '-
和5 '-末端连接,并开发用于表征
5 ′-末端连接步骤和所需的因素。这项研究可能揭示
抑制剂的潜在新靶点,并为药物
筛选从研究整合位点选择中获得的信息
可能导致一种新的方法,在特定的位置插入外源基因,
网站.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Samson A Chow其他文献
FUNCTIONAL EVALUATION OF XMRV INFECTION AND PROSTATE CANCER INITIATION IN PRIMARY PROSTATE CELLS OF GENETICALLY SUSCEPTIBLE INDIVIDUALS
- DOI:
10.1016/s0022-5347(09)60541-3 - 发表时间:
2009-04-01 - 期刊:
- 影响因子:
- 作者:
Maahum Haider;Wayne W Grady;Samson A Chow;Isla P. Garraway - 通讯作者:
Isla P. Garraway
Samson A Chow的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Samson A Chow', 18)}}的其他基金
Characterizing the binding between HIV-1 integrase and capsid and the role of the interaction in modulating the uncoating process
表征 HIV-1 整合酶和衣壳之间的结合以及相互作用在调节脱衣过程中的作用
- 批准号:
8924724 - 财政年份:2015
- 资助金额:
$ 22.69万 - 项目类别:
Role of HIV-1 IN during reverse transcription and uncoating
HIV-1 IN 在逆转录和脱壳过程中的作用
- 批准号:
8316404 - 财政年份:2011
- 资助金额:
$ 22.69万 - 项目类别:
Role of HIV-1 IN during reverse transcription and uncoating
HIV-1 IN 在逆转录和脱壳过程中的作用
- 批准号:
8545193 - 财政年份:2011
- 资助金额:
$ 22.69万 - 项目类别:
Role of HIV-1 IN during reverse transcription and uncoating
HIV-1 IN 在逆转录和脱壳过程中的作用
- 批准号:
8139493 - 财政年份:2011
- 资助金额:
$ 22.69万 - 项目类别:
Role of HIV-1 IN during reverse transcription and uncoating
HIV-1 IN 在逆转录和脱壳过程中的作用
- 批准号:
8726439 - 财政年份:2011
- 资助金额:
$ 22.69万 - 项目类别:
Binding Between HIV-1 RT and IN and Its Functional Signification
HIV-1 RT与IN的结合及其功能意义
- 批准号:
7635911 - 财政年份:2008
- 资助金额:
$ 22.69万 - 项目类别:
Binding Between HIV-1 RT and IN and Its Functional Signification
HIV-1 RT与IN的结合及其功能意义
- 批准号:
7555091 - 财政年份:2008
- 资助金额:
$ 22.69万 - 项目类别:
PET DETECTION AND INTEGRASE INHIBITORS OF FIV INFECTION
PET 检测和 FIV 感染整合抑制剂
- 批准号:
6171022 - 财政年份:1999
- 资助金额:
$ 22.69万 - 项目类别:
PET DETECTION AND INTEGRASE INHIBITORS OF FIV INFECTION
PET 检测和 FIV 感染整合抑制剂
- 批准号:
6374070 - 财政年份:1999
- 资助金额:
$ 22.69万 - 项目类别:
PET DETECTION AND INTEGRASE INHIBITORS OF FIV INFECTION
PET 检测和 FIV 感染整合抑制剂
- 批准号:
6020030 - 财政年份:1999
- 资助金额:
$ 22.69万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 22.69万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 22.69万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 22.69万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 22.69万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 22.69万 - 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 22.69万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 22.69万 - 项目类别:
Studentship